Patient preferences for treatment of rheumatoid arthritis. Issue 11 (5th March 2004)

• Record Type: Journal Article
• Authors: Fraenkel, L; Bogardus, S T; Concato, J; Felson, D T; Wittink, D R
• Is Part Of: Annals of the rheumatic diseases. Volume 63:Issue 11(2004)
• Page Start: 1372
• Page End: 1378
• Publication Date: 2004-03-05
• Subjects: ACA, Adaptive Conjoint Analysis -- DMARD, disease modifying antirheumatic drug -- RA, rheumatoid arthritis -- TNF, tumour necrosis factor; patient participation -- rheumatoid arthritis -- disease modifying antirheumatic drugs; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2003.019422
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: To elicit treatment preferences of patients with rheumatoid arthritis (RA) for disease modifying antirheumatic drugs (DMARDs) with varying risk profiles. Methods: Patient values for 16 DMARD characteristics were ascertained using published data about side effects, effectiveness, and cost. Patient preferences were determined by Adaptive Conjoint Analysis, an interactive computer program that predicts preferences by asking patients to make trade-offs between specific treatment characteristics. Simulations were run to derive preferences for four drugs: methotrexate, gold, leflunomide, and etanercept, under different risk-benefit scenarios. Infliximab was not included because it is given with methotrexate, and we did not include preferences for combination therapy. Based on each patient's expressed preferences, and the characteristics of the treatments available at the time of the study, the option that best fitted each patient's perspective was identified. Results: 120 patients (mean age 70 years) were interviewed. For the base case scenario (which assumed the maximum benefits reported in the literature, a low probability of adverse effects, and low equal monthly "co-pays" (out of pocket costs)), 95% of the respondents preferred etanercept over the other treatment options. When all four options were described as being equally effective, 88% continued to prefer etanercept owing to its safer short term adverse effect profile. Increasing etanercept's co-pay to $30.00 decreased the percentage of patients preferring this option to 80%. Conclusions: In this study, older patients with RA, when asked to consider trade-offs between specific risk and benefits, preferred etanercept over other treatment options. Preference for etanercept is explained by older patients' risk aversion for drug toxicity.